Organoid-guided therapy at scale
Organoid-guided therapy means routinely growing a piece of each patient's tumour and testing drugs on it before choosing, rather than relying on genetics alone.
Patient-derived organoids reproduce genotype and drug response, and prospective series in colorectal, pancreatic and ovarian cancer report meaningful correlation between ex vivo sensitivity and clinical response. Turning that into routine care needs take rates above 70%, results inside three weeks, and a randomised trial showing that acting on the result helps. Companies including Xilis and Curesponse and several academic programmes are pushing on throughput; the randomised evidence does not exist yet.
How it works
Fresh tumour tissue is dissociated and cultured in matrix; a drug panel is applied and viability read out, producing a per-patient sensitivity profile.
- Phenotype captures what genotype misses
- Tests combinations and sequences
- Useful when no actionable mutation is found
- Take rate and turnaround time
- No stroma or immune compartment in most systems
- No randomised proof of benefit
Latest papers
topQuery for this technology: (TITLE:"Organoid-guided therapy at scale" OR ABSTRACT:"Organoid-guided therapy at scale") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Organoid-guided therapy at scale, not a curated reading list.
Pages like this
not linked directly; found by shared links- TechnologyChronotherapy: timing treatment to the body clock
Shares Paths to cures: interception, eradication, control, Radical oncology: what could change the war by 2035 and the tags frontier, promising.
- TechnologyN-of-1 and rapid platform trials
Shares Radical oncology: what could change the war by 2035, Functional (ex vivo) drug testing and the tags frontier, promising.
- TechnologyRadioligand plus DNA-repair inhibitor combinations
Shares Paths to cures: interception, eradication, control, Radical oncology: what could change the war by 2035 and the tags frontier, promising.
- TechnologyCachexia-directed therapy (GDF-15 blockade)
Shares Paths to cures: interception, eradication, control, Radical oncology: what could change the war by 2035 and the tags frontier, promising.
- TechnologySpatial-omics-guided treatment selection
Shares Paths to cures: interception, eradication, control, Radical oncology: what could change the war by 2035 and the tags frontier, promising.
- TechnologyContinuous and near-continuous ctDNA monitoring
Shares Paths to cures: interception, eradication, control, Radical oncology: what could change the war by 2035 and the tags frontier, promising.
- TechnologyLogic-gated therapeutics (AND, NOT gates)
Shares Paths to cures: interception, eradication, control, Radical oncology: what could change the war by 2035 and the tags frontier, promising.
- TechnologyIn situ vaccination
Shares Paths to cures: interception, eradication, control, Radical oncology: what could change the war by 2035 and the tags frontier, promising.